DelveInsight's Tenosynovial Giant Cell Tumors (TSGCTs) - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Tenosynovial Giant Cell Tumors (TSGCTs) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Tenosynovial Giant Cell Tumors Epidemiology Forecast - 2032

1. Key Insights
2. Report Introduction
3. TGCT Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of TGCT by countries in 2021
3.2. Patient Share (%) Distribution of TGCT by countries by 2034
4. Executive Summary of Tenosynovial Giant Cell Tumor (TGCT)
5. Disease Background and Overview
5.1. Introduction of Tenosynovial Giant Cell Tumors
5.2. Etiology of Tenosynovial Giant Cell Tumor
5.3. Molecular biology of Tenosynovial Giant Cell
5.4. Classification of Tenosynovial Giant Cell Tumors (TGCT)
5.4.1. Pigmented villonodular synovitis (PVNS)
5.4.2. Conventional PVNS (intra-articular, diffuse-type giant cell tumor)
5.4.3. Giant cell tumor of the tendon sheath
5.5. Clinical features
5.6. Subdivisions of Tenosynovial Giant Cell Tumor on the basis of Cellular Division
5.6.1. Diffuse-type giant cell tumor
5.6.2. Intra-articular giant cell tumor of the tendon sheath or pigmented villonodular synovitis
5.6.3. Malignant TGCT (malignant PVNS)
5.7. Pathogenesis
5.8. Biomarkers
5.9. Diagnosis
5.9.1. Clinical evaluation
5.9.2. Imaging features
5.9.3. Differential diagnosis
5.9.4. Diagnosis algorithm
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Assumptions and Rationale: The 7MM
6.3. Epidemiology Methodology
6.4. Incident Cases of TGCT in the 7MM
6.5. The United States
6.5.1. Incident cases of TGCT in the United States
6.5.2. Growth pattern-specific incident cases of TGCT in the United States
6.5.3. Gender-specific incident cases of localized TGCT in the United States
6.5.4. Gender-specific incident cases of diffuse TGCT in the United States
6.5.5. Tumor localization of localized TGCT in the United States
6.5.6. Tumor localization of diffuse TGCT in the United States
6.6. EU4 and the UK
6.6.1. Incident cases of TGCT in EU4 and the UK
6.6.2. Growth pattern-specific incident cases of TGCT in EU4 and the UK
6.6.3. Gender-specific incident cases of Localized TGCT in EU4 and the UK
6.6.4. Gender-specific incident cases of diffuse TGCT in EU4 and the UK
6.6.5. Tumor localization of localized TGCT in EU4 and the UK
6.6.6. Tumor localization of diffuse TGCT in EU4 and the UK
6.7. Japan
6.7.1. Incident cases of TGCT in Japan
6.7.2. Growth pattern-specific incident cases of TGCT in Japan
6.7.3. Gender-specific incident cases of localized TGCT in Japan
6.7.4. Gender-specific incident cases of diffuse TGCT in Japan
6.7.5. Tumor localization of localized TGCT in Japan
6.7.6. Tumor localization of diffuse TGCT in Japan
7. Appendix
7.1. Bibliography
7.2. Acronyms and Abbreviations
7.3. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
 
10. About DelveInsight

DelveInsight's "Tenosynovial Giant Cell Tumors (TSGCTs) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Tenosynovial Giant Cell Tumors (TSGCTs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Tenosynovial Giant Cell Tumors (TSGCTs) Epidemiology

Tenosynovial Giant Cell Tumors (TSGCTs) - Epidemiology Forecast - 2034

DelveInsight's Tenosynovial Giant Cell Tumors (TSGCTs) - Epidemiology Forecast 2034 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology..